“Primer shot” fractionation with an early treatment break is theoretically superior to consecutive weekday fractionation schemes for early-stage non-small cell lung cancer

The use of hypofractionation and stereotactic radiotherapy is increasing for all cancers. In breast[1] and prostate cancer[2], schedules have been reduced to 5 fractions. Similarly, hypofractionation is ideal for many early-stage non-small-cell lung cancer (NSCLC), given the small amount of lung tissue in the irradiated volume[3]. The resulting local failure (LF) rate is low, especially for peripherally located tumors[4] that can receive more effective fractionation regimes, typically to biologically effective doses (BED) of>100 Gy [5].

Source: Radiotherapy and Oncology - November 14, 2023 Category: Radiology Authors: Z.A.R. Gouw, J. Jeong, A. Rimner, N.Y. Lee, A. Jackson, A. Fu, J-J. Sonke, J.O. Deasy Tags: Original Article Source Type: research